Does Horizon Blue Cross Blue Shield of New Jersey Cover Forteo?

What Is Forteo and Why Do Women Need It?

Forteo (teriparatide) is a synthetic form of parathyroid hormone (PTH 1-34) given as a once-daily subcutaneous injection. Rather than slowing bone breakdown the way bisphosphonates do, it actively stimulates new bone formation, making it one of the few truly anabolic osteoporosis therapies available.

For women, this distinction matters enormously. Postmenopausal bone loss is driven by estrogen withdrawal, which tips the balance between bone resorption and formation sharply toward breakdown. Studies published in the New England Journal of Medicine showed that teriparatide reduced new vertebral fractures by 65% and non-vertebral fragility fractures by 53% in postmenopausal women with osteoporosis, results that no oral bisphosphonate has matched in head-to-head anabolic comparison.

Forteo is approved by the FDA for postmenopausal women with osteoporosis at high risk for fracture, men with primary or hypogonadal osteoporosis, and women and men with glucocorticoid-induced osteoporosis. The maximum treatment duration is 24 months lifetime. After that, you transition to an antiresorptive agent to preserve the bone gains.

How Forteo Differs From Bisphosphonates

Bisphosphonates (alendronate, risedronate, zoledronic acid) block osteoclast activity. They are effective, well-studied, and inexpensive. Forteo recruits osteoblasts to build new bone matrix. The practical difference: women with very severe osteoporosis (T-score at or below -3.0), multiple vertebral fractures, or who have failed or cannot tolerate bisphosphonates get measurably more benefit from an anabolic agent.

Which Women Are Typically Prescribed Forteo?

The North American Menopause Society (NAMS) 2023 position statement on osteoporosis identifies anabolic therapy as appropriate first-line treatment for women at very high fracture risk, defined as a T-score at or below -2.5 with one or more fragility fractures, or a T-score at or below -3.0 regardless of fracture history. Clinicians also prescribe Forteo for women who have experienced fractures despite bisphosphonate therapy, who have severe glucocorticoid-induced osteoporosis, or who have conditions like rheumatoid arthritis that accelerate bone loss.

How Horizon BCBS NJ Covers Forteo: The Basics

Horizon Blue Cross Blue Shield of New Jersey is the largest health insurer in New Jersey, covering roughly 3.8 million members across commercial, Medicare Advantage, and Medicaid managed-care products. Coverage rules differ across these product lines, but the general framework for Forteo is consistent.

Commercial Plans (Employer-Sponsored and Individual Market)

On Horizon's commercial formularies, Forteo appears on the specialty drug tier, typically Tier 4 or Tier 5. Cost-sharing at that tier can range from 20% to 33% coinsurance, or a flat specialty copay that varies by plan design. The actual out-of-pocket number at a retail or specialty pharmacy without any manufacturer assistance can still be several hundred dollars per month even with coverage.

Prior authorization is required on every commercial plan that lists Forteo. Horizon's clinical coverage criteria for anabolic bone agents generally align with FDA labeling and with the American Association of Clinical Endocrinologists (AACE) 2020 clinical practice guidelines, which reserve anabolic therapy for high- and very-high-risk fracture categories. Your prescriber will need to document:

• A DEXA scan T-score of -2.5 or lower at the spine, hip, or femoral neck
• Fracture risk assessment (FRAX score is commonly requested)
• Prior trial of, contraindication to, or intolerance of a bisphosphonate or other antiresorptive agent
• Absence of contraindications (see pregnancy section below and the osteosarcoma risk discussion)

Medicare Advantage Plans

Horizon offers several Medicare Advantage products in New Jersey. For Medicare beneficiaries, Forteo falls under Part D (prescription drug benefit), not Part B, because it is self-administered. The coverage determination follows CMS national coverage analysis as well as Horizon's own formulary. Step therapy waivers are more accessible under the federal SUPPORT for Patients and Communities Act provisions; if you have already tried and failed a bisphosphonate before enrolling in a Medicare Advantage plan, that prior therapy may satisfy step therapy requirements without repeating it.

Medicaid Managed Care (Horizon NJ Health)

Horizon NJ Health, the Medicaid managed-care arm, covers Forteo for members who meet New Jersey Medicaid medical necessity criteria. The state Medicaid program follows New Jersey Division of Medical Assistance and Health Services (DMAHS) drug utilization review protocols, which require prior authorization and typically limit the approval period to 12 months with renewal review. Cost-sharing for Medicaid members is minimal, but the documentation requirements are equally rigorous.

Prior Authorization: What Your Prescriber Needs to Submit

Prior authorization is not optional. Without it, Forteo will be rejected at the pharmacy. Here is exactly what the PA submission typically requires.

Required Clinical Documentation

• Most recent DEXA scan report (within the past 24 months) with T-scores at spine and hip
• FRAX 10-year fracture probability, ideally calculated with bone mineral density
• Documentation of prior osteoporosis treatment: drug name, dose, duration, reason for discontinuation or inadequacy
• Diagnosis code: M81.0 (postmenopausal osteoporosis without fracture) or M80.00 (age-related osteoporosis with fragility fracture)
• Prescribing physician specialty (endocrinology, rheumatology, or OB-GYN with documented bone-health expertise strengthens the case)
• Patient weight and height (relevant to fracture risk calculation)
• Calcium and vitamin D supplementation status

Step Therapy: The Bisphosphonate Requirement

Most Horizon commercial plans require documented failure of, intolerance to, or contraindication to at least one bisphosphonate before approving Forteo. Alendronate (Fosamax) is the most commonly required step. If you have esophageal disease, Barrett's esophagus, inability to remain upright for 30 minutes, or severe renal impairment (eGFR <35 mL/min/1.73m²), your prescriber can document contraindication to oral bisphosphonates and request a step therapy exception.

New Jersey has step therapy exception protections under N.J.S.A. 26:2SS-1 et seq., which requires insurers to respond to a step therapy exception request within 72 hours (or 24 hours for urgent cases). Your prescriber initiates this by submitting the exception alongside the PA request.

What Happens If the PA Is Denied

Denials are common on the first submission, often because documentation is incomplete rather than because the patient truly does not qualify. The appeals pathway:

1. Internal appeal to Horizon's medical review department. Submit additional clinical notes, the specialist's letter of medical necessity, and any peer-reviewed literature supporting anabolic-first therapy in your fracture-risk category.
2. External appeal to an independent review organization designated by the New Jersey Department of Banking and Insurance. New Jersey law requires Horizon to comply with an external reviewer's decision.
3. Peer-to-peer review: your prescriber calls Horizon's medical director directly. This step resolves many denials before the formal appeals process is needed.

Biosimilar and Alternative Coverage: What Horizon May Prefer

Horizon's specialty formulary may prefer Bonsity or Tymlos over brand Forteo. This directly affects your coverage path.

Bonsity (Teriparatide Biosimilar)

Bonsity, manufactured by Alvogen, is an FDA-approved biosimilar to Forteo. The FDA granted Bonsity biosimilar designation based on comparative clinical data demonstrating no clinically meaningful differences from the reference product. Many commercial insurers, including some Horizon plans, have placed Bonsity on a preferred specialty tier with lower cost-sharing than brand Forteo. If your plan prefers Bonsity, your prescriber may need to write specifically for the biosimilar, or Horizon may allow substitution at the pharmacy.

Tymlos (Abaloparatide)

Tymlos (abaloparatide 80 mcg/day) is a related anabolic agent with a similar but distinct mechanism. The ACTIVE trial showed a 43% reduction in new vertebral fractures versus placebo in postmenopausal women, with a fracture incidence of 0.58% versus 4.22% in the placebo group over 18 months. Some Horizon formularies place Tymlos on a preferred tier relative to brand Forteo. If your clinical situation allows either agent, your prescriber can check formulary status before writing the prescription.

Evenity (Romosozumab)

Evenity (romosozumab) is a sclerostin inhibitor with dual anabolic and antiresorptive activity, given as monthly subcutaneous injections for 12 months. It is generally covered under a separate PA pathway and carries a black-box warning for cardiovascular events. Women with a prior heart attack or stroke are not candidates.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Forteo is contraindicated in pregnancy. This is not a relative caution. It is an absolute contraindication.

Pregnancy

Teriparatide is classified as FDA Pregnancy Category not assigned under the current labeling system (labeling updated post-2015), but animal studies showed fetal skeletal abnormalities at exposures above the clinical dose. The FDA prescribing information states that Forteo should not be used in pregnant women, and that women of childbearing potential should use effective contraception during treatment.

Human data in pregnancy is essentially absent for this drug, which is expected given that the indicated population is postmenopausal women and older men. If you are in perimenopause and still having periods, even irregular ones, pregnancy is possible. You must use reliable contraception throughout the 24-month Forteo treatment course.

Perimenopausal Women: A Specific Note

Perimenopause typically spans 4 to 8 years before the final menstrual period. During this window, ovarian function is erratic. Women in early perimenopause can and do conceive, sometimes unexpectedly. ACOG Committee Opinion 762 notes that contraception should be continued until 12 months of amenorrhea have been confirmed in women over 50, and until 24 months of amenorrhea in women under 50. If your prescriber is considering Forteo before menopause is confirmed, contraception planning is a mandatory conversation, not an optional one.

Lactation

There are no human data on teriparatide transfer into breast milk. Given the molecular size of the peptide and the likelihood of gastric degradation, systemic absorption by a nursing infant is probably low. Given the indicated population, lactation is rarely relevant clinically. If you are postpartum and experiencing severe glucocorticoid-induced osteoporosis (a real, if rare, scenario in women on long-term steroids for inflammatory conditions), discuss the risk-benefit with your prescriber and a lactation medicine specialist before starting Forteo.

Postpartum Osteoporosis

Pregnancy- and lactation-associated osteoporosis (PLO) is a rare condition affecting women typically in the third trimester or shortly after delivery. Forteo has been used off-label in case series for PLO with encouraging results, but insurance coverage for this off-label indication requires individualized appeals and strong clinical documentation. A 2019 systematic review in Osteoporosis International identified teriparatide as the most frequently used anabolic agent in PLO case series, with significant BMD gains reported.

Life-Stage Coverage Considerations

Reproductive Years and PCOS

Young women with PCOS who develop premature bone loss due to androgen excess, irregular cycles, and low estrogen exposure represent an emerging population with bone fragility risk. Coverage for Forteo in premenopausal women under 50 is very difficult to obtain from any commercial insurer, including Horizon, because the evidence base for teriparatide in this group is limited to small studies. Bisphosphonates are also problematic in women of reproductive age because of their long skeletal half-life and uncertain fetal effects. Hormonal management of PCOS and calcium/vitamin D optimization are the realistic first steps.

Postmenopausal Women: The Core Covered Population

The vast majority of Forteo approvals at Horizon will be for postmenopausal women aged 50 to 80 with documented severe osteoporosis. In this group, the clinical evidence is strongest and the PA criteria most clearly met. The National Osteoporosis Foundation (now the BHOF) estimates that 1 in 2 women over 50 will have an osteoporosis-related fracture in their lifetime, underscoring why coverage decisions in this group carry serious public health weight.

Women on Long-Term Glucocorticoids

Women with rheumatoid arthritis, lupus, inflammatory bowel disease, or asthma who require long-term prednisone are at accelerated risk for glucocorticoid-induced osteoporosis (GIO). The American College of Rheumatology 2022 guidelines recommend anabolic therapy (teriparatide or abaloparatide) over antiresorptive therapy as the preferred initial treatment for adults at high or very high fracture risk on glucocorticoids. This guideline language is your strongest tool when appealing a Horizon denial in a GIO patient, because the standard-of-care argument directly challenges the step-therapy rationale.

The Osteosarcoma Black-Box Warning: What It Means for Coverage and for You

Forteo carries a black-box warning about osteosarcoma risk, based on rat studies showing dose- and duration-dependent osteosarcoma with teriparatide. In humans, post-marketing surveillance data accumulated over more than 15 years have not established a causal relationship between teriparatide and osteosarcoma. The FDA removed the REMS program requirement for Forteo in 2020 after determining that the osteosarcoma signal in humans did not materialize at clinical doses.

The warning still appears in the label, and Horizon may cite it in prior authorization criteria to exclude patients with:

• Prior radiation therapy to the skeleton
• Paget's disease of bone
• Unexplained alkaline phosphatase elevation
• Open epiphyses (relevant in rare pediatric off-label scenarios)
• Existing bone malignancy or history of skeletal metastases

If any of these apply to you, Forteo coverage will be denied, and alternative anabolic strategies should be explored.

How to Reduce Your Out-of-Pocket Cost

Even with Horizon coverage, specialty-tier cost-sharing can be significant. Here are specific options.

Eli Lilly's Forteo Savings Card

Eli Lilly offers a savings card for commercially insured patients that may reduce your monthly copay. Eligibility excludes Medicare and Medicaid beneficiaries. Visit the Forteo manufacturer site or call Lilly's patient support line to verify current terms, as maximum savings amounts change annually.

Lilly Cares Patient Assistance Program

For uninsured or underinsured patients who meet income criteria, the Lilly Cares Foundation provides Forteo at no cost. Income thresholds are updated annually. Your prescriber's office can help initiate the application.

Specialty Pharmacy Copay Assistance

Horizon typically requires Forteo to be dispensed through a contracted specialty pharmacy (commonly Accredo or CVS Specialty). These pharmacies have financial counselors who can identify additional assistance programs specific to your situation.

Appealing to Bonsity If Cost Is the Issue

If brand Forteo is on a higher cost-sharing tier than Bonsity on your specific Horizon plan, ask your prescriber to write for Bonsity instead. Same mechanism, FDA-confirmed bioequivalence, lower tier placement on many formularies. This one step can cut specialty cost-sharing substantially.

Who This Is Right For and Who Should Consider Alternatives

Strong Candidates for Forteo Coverage Approval

• Postmenopausal women with T-score at or below -2.5 and at least one fragility fracture
• Women with T-score at or below -3.0 regardless of fracture history
• Women who fractured on bisphosphonate therapy
• Women with severe GIO at high fracture risk on ACR 2022 criteria
• Women with documented bisphosphonate intolerance or contraindication

Women Who Will Likely Face Coverage Barriers

• Premenopausal women under 45 without an exceptional clinical scenario
• Women with a prior heart attack who may be better served by Evenity avoidance and antiresorptive therapy
• Women with osteopenia (T-score between -1.0 and -2.5) without fracture history
• Women with active or recent malignancy

When Antiresorptives Are the Better Starting Point

For most postmenopausal women with moderate osteoporosis (T-score between -2.5 and -3.0, no fractures), bisphosphonates remain the evidence-backed, cost-effective, and easily covered first choice. The HORIZON Key Fracture Trial demonstrated that zoledronic acid reduced hip fracture risk by 41% and vertebral fracture risk by 70% over three years in postmenopausal women, results that represent meaningful fracture protection at a fraction of Forteo's cost.

A Word on the Evidence Gap for Women

Women have not been under-represented in osteoporosis trials the way they have in cardiovascular or oncology research. The postmenopausal osteoporosis trial population is predominantly female by design. What is less well-studied is teriparatide in younger women (under 50), in perimenopausal women with hormone therapy co-administration, and in specific conditions like PCOS-related bone loss or PLO. When your situation falls outside the core postmenopausal trial population, your prescriber is working from extrapolated data, not direct evidence. Be explicit with your insurer about what evidence exists and where the gaps are. This honesty can support an individualized medical necessity argument.

As WomanRx reviewer Rachel Goldberg, MD notes: "The prior authorization process for Forteo rewards documentation. Women who come in with their DEXA report, their FRAX score, their fracture history clearly written out, and a record of what they tried before, those are the patients whose PAs get approved on the first submission. The denials I see are almost always about incomplete paperwork, not about a patient who genuinely doesn't qualify."